Review and cross-validation of gene expression signatures and melanoma prognosis.
about
One-step extrapolation of the prediction performance of a gene signature derived from a small studyClinical and biological determinants of melanoma progression: Should all be considered for clinical management?Isolation and molecular characterization of circulating melanoma cellsAn attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma.Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.Vascular dysfunction and increased metastasis of B16F10 melanomas in Shb deficient mice as compared with their wild type counterparts.Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.The immune-related role of BRAF in melanoma.A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis.Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma.A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor CellsGermline determinants of clinical outcome of cutaneous melanoma.Skinomics: past, present and future for diagnostic microarray studies in dermatology.Genetic alterations and personalized medicine in melanoma: progress and future prospects.Evolving role of tumor antigens for future melanoma therapies.Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma.Prognostic and predictive biomarkers in melanoma: an update.Biomarkers in melanoma.The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.Molecular pathology of cutaneous melanomaLymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neckImmune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment
P2860
Q28392088-0C1B66EE-2D34-46F6-AA15-EFAEB2326185Q30252150-822201EF-30EA-4BD2-B446-B6814B31DEB4Q33835938-5E02EB5F-2FF3-474F-9B38-5F0C8643BABFQ34482829-82C70142-3084-49BF-B8EE-A777E04F5FFCQ34708265-6FFBD52A-1CAE-4ACE-A3F7-B922D30CBB50Q35217621-C7053F82-8CBA-445A-8847-B3D66F52CFECQ35358884-B9C26793-6E28-4EF1-92FF-C977F8D549AFQ35793900-0475DEC1-099B-4C41-84AF-388298B676E5Q35847321-3F629E5B-2861-4D4F-9A68-FB441ABDA70BQ36773305-EA260145-DEC5-4E00-B382-19F6BC0A5639Q37046631-39F1F875-A161-4429-9AB8-01EC6B06D497Q37214957-37AD81A4-CDB7-43BD-B727-1DAABD61E56DQ37258423-E07C4038-81DF-4DF4-BA11-D060E73538B2Q38154933-CF1E1D29-FA92-44A8-8225-542D62629771Q38186704-268FA53F-2FE2-4333-8102-F45D4C8ED7CBQ38232855-B25B5A83-8724-4188-AED9-22CC8838188DQ38312053-014EDEE7-F0AB-465D-9C9A-EA7916518173Q38381558-1E25839D-5328-444B-ABDD-FE83B1D7F5EFQ38653619-97A38BE9-54B5-4AE7-BA2E-4C19EF7650D4Q38911167-2675D1FB-CCAC-475A-BDC1-A134A60E0CE9Q41696842-52AD85D0-49C5-4F99-AA2A-B27F94FED5E2Q44133547-5848A1DA-05C9-4985-AD91-6B2E2AA9BBB9Q50934746-75DDD53A-AD04-4806-BAB6-C982C32B4B67Q56428911-4BE2EC60-059C-48F7-9E5A-9DCC1BBF7F4FQ56967823-B47D5DFE-83CF-4BC0-B3B5-9808E1AD53ABQ59275946-3768151B-1EDD-4CB2-BE88-8C1D6E2CB231
P2860
Review and cross-validation of gene expression signatures and melanoma prognosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Review and cross-validation of gene expression signatures and melanoma prognosis.
@en
Review and cross-validation of gene expression signatures and melanoma prognosis.
@nl
type
label
Review and cross-validation of gene expression signatures and melanoma prognosis.
@en
Review and cross-validation of gene expression signatures and melanoma prognosis.
@nl
prefLabel
Review and cross-validation of gene expression signatures and melanoma prognosis.
@en
Review and cross-validation of gene expression signatures and melanoma prognosis.
@nl
P50
P356
P1476
Review and cross-validation of gene expression signatures and melanoma prognosis
@en
P2093
Anna E Campain
P2888
P304
P356
10.1038/JID.2011.305
P407
P577
2011-09-29T00:00:00Z